Tramadol 200mg is a synthetic opioid analgesic used to treat moderate to moderately severe pain. The 200mg dose is a higher-strength extended-release (ER) formulation, typically prescribed for around-the-clock pain management rather than as-needed use. Here’s a factual breakdown based on established medical sources like the FDA, EMA, and pharmacology references (e.g., Lexicomp, Micromedex):

Key Facts

Effectiveness Evidence

• Clinical Trials: In studies (e.g., FDA approval data for Ultram ER), 200mg daily reduced pain scores by 30-50% vs. placebo in chronic pain patients (e.g., low back pain trials with n>1,000). Comparable to other opioids like oxycodone at equipotent doses but with less respiratory depression.
• Meta-Analyses: Cochrane reviews (2020) confirm moderate efficacy for neuropathic pain (NNT=4.7 for 30% pain relief), though inferior to stronger opioids for severe pain.
• Limitations: Tolerance develops in 20-30% of long-term users; not first-line due to abuse potential.

Side Effects (Common >5%)

• Nausea/vomiting (20-40%)
• Dizziness/somnolence (15-30%)
• Constipation (10-20%)
• Headache, dry mouth

Serious Risks (1-5% incidence):

• Serotonin Syndrome: Risk with SSRIs/SNRIs (symptoms: agitation, hyperthermia, seizures). Case reports show 1:1,000 risk.
• Seizures: Dose-dependent (0.1-1% at >300mg/day); higher in epileptics or with tramadol overdose.
• Respiratory Depression: Rare at therapeutic doses but fatal in overdose (binds μ-receptors weakly, LD50 ~500mg/kg in animals).
• Hypogonadism: Chronic use suppresses testosterone (studies show 20-50% drop in levels).
• Dependence/Withdrawal: DSM-5 classifies as opioid use disorder risk; withdrawal mimics flu + anxiety (incidence 10-15% in >3 months use).

Contraindications & Warnings

• Avoid in: Children <12, post-op in kids <18 (FDA black box for respiratory risk), acute intoxication, severe respiratory depression.
• Drug Interactions: MAOIs (within 14 days), SSRIs (serotonin syndrome), CYP2D6 inhibitors (e.g., fluoxetine doubles exposure).
• Overdose: 200mg single dose rarely fatal in adults (therapeutic index high), but >1g risky. Naloxone reverses opioid effects partially.
• Pregnancy: Category C; neonatal withdrawal reported (FDA REMS program).

Pharmacokinetics

• Bioavailability: 75% (ER form)
• Half-Life: 6-7 hours (prolonged in elderly/renal impairment: up to 16 hours)
• Metabolism: CYP2D6 to active O-desmethyltramadol (poor metabolizers: 7-10% population, reduced efficacy)

Evidence Sources: FDA label (Ultram ER, 2006), EMA SmPC, BNF 2023, studies in Pain (e.g., DOI:10.1016/j.pain.2006.08.005).

Critical Note: This is general info, not medical advice. Dosing must be individualized by a doctor—200mg isn’t suitable for everyone (e.g., max 300mg/day in elderly). Self-medication risks overdose, addiction, or death. Consult a healthcare provider or pharmacist for personal use, and check local regulations